{"analyses":[{"ciLowerLimit":"0.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.85","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.70","statisticalMethod":"1-sided, Log Rank Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.5","upperLimit":"10.4","value":"8.6"},{"groupId":"OG001","lowerLimit":"5.3","upperLimit":"7.0","value":"6.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"description":"OS is defined as the length of time from the date of randomization until the date of death due to any cause in all randomized participants","dispersionType":"95% Confidence Interval","groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"OG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"OG001","title":"Investigator Chosen Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The ITT analysis set included all randomized participants","reportingStatus":"POSTED","timeFrame":"Approximately 2 years and 10 months from date of first randomization","title":"Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set","type":"PRIMARY","unitOfMeasure":"Months"}